Protalix BioTherapeutics, Inc.
PLX · AMEX
Market closed$2.38$0.070000 (+3.03%)After hours $2.38 · 0.00%
Key statistics
Previous close$2.31
Open$2.25
Day high$2.41
Day low$2.25
52-week high$3.19
52-week low$1.41
Market cap191.76M
Volume516.03K
Average volume722.26K
P/E ratio13.08
Forward P/E—
EPS0.18
Dividend yield0.00%
Market context
Why it moved
PLX edged higher amid modest buying interest, likely driven by stabilizing sentiment in the energy sector after recent oil-related selling pressure, as broader market conditions supported a mild recovery in the stock.
What is happening
Recent company-specific developments and publisher coverage.
Stock Titan · June 25, 2026Protalix (NYSE: PLX) investors approve directors, pay and expanded stock planPR Newswire · May 13, 2026Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business ResultsSeeking Alpha · March 24, 2026Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance (NYSE:PLX)Simply Wall Street · March 19, 2026Protalix BioTherapeutics (PLX) TTM Loss Challenges Bullish Profitability Narratives After FY 2025 ResultsTradingView · March 18, 2026Protalix BioTherapeutics 2025 10-K: $52.7M Revenue, $(6.6)M Net LossPR Newswire · March 11, 2026Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 Benzinga · May 13, 2026Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call Benzinga · May 13, 2026Protalix BioTherapeutics Q1 EPS $0.05 Misses $0.06 Estimate, Sales $33.750M Beat $11.468M Estimate Benzinga · March 19, 2026HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target Benzinga · March 18, 2026Protalix BioTherapeutics Expects FY26 Total Revenue To Range From ~$78M To $83M Including $25M Milestone Which Protalix Is Entitled To From Chiesi Benzinga · March 18, 2026Protalix BioTherapeutics Q4 EPS $(0.06) Misses $0.04 Estimate, Sales $9.300M Miss $16.918M Estimate Benzinga · March 9, 2026The European Commission Approves 2mg/kg Every-4-weeks Dosing Regimen For Chiesi And Protalix Biotherapeutics' Elfabrio (Pegunigalsidase Alfa) For Fabry Disease Patients Who Are Stable With An Enzyme Replacement Therapy Mt Newswire · January 30, 2026Protalix Fabry Disease Treatment Recommended for Approval by EMA Committee Benzinga · January 30, 2026Chiesi Group's Unit And Protalix BioTherapeutics Say CHMP Of EMA Issues Positive Opinion Recommending Approval Of 2mg/Kg E4W Dosing Regimen For Elfabrio In Fabry Disease Adult Patients Stable With ERT Treatment